Acquisition of Totipotent RX (Details) (USD $)	0 Months Ended	1 Months Ended	3 Months Ended		9 Months Ended
	Feb. 28, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014 Subsidiary	Mar. 31, 2013	Feb. 18, 2014 Officer
Business Acquisition [Line Items]
Acquisition related costs			$ 484,000		$ 1,725,000
Number of convertible shares in exchange of warrants issued (in shares)		1,668,400	1,668,400		1,668,400
Business Acquisition, Pro Forma Information [Abstract]
Repayment of related party notes payable					150,000	0
TotipotentRX Corporation [Member]
Business Acquisition [Line Items]
Number of wholly owned subsidiaries					2
Recorded revenues during the quarter		120,000
Recorded loss during the quarter		60,000
Aggregate number of shares issued (in shares)	12,490,841
Percentage of common stock issued to acquiree shareholders (in hundredths)							38.00%
Fair value of aggregate number of shares issued							27,105,000
Number of convertible shares in exchange of warrants issued (in shares)							61,020
Warrant issued in relation to business acquisition (in shares)							61,020
Fair value of common stock in exchange of warrants issued							52,000
Purchase Price [Abstract]
ThermoGenesis common shares and warrants							27,174,000
Fair value of assets acquired [Abstract]
Cash							351,000
Receivables							171,000
Inventories							191,000
Clinical protocols							6,041,000
Other intangible assets							2,714,000
Property and equipment							325,000
Other assets							132,000
Total assets							9,925,000
Fair value of liabilities assumed [Abstract]
Accounts payable							627,000
Related party notes payable							337,000
Other liabilities							680,000
Total liabilities							1,644,000
Net assets acquired							8,281,000
Preliminary goodwill							18,893,000
Business Acquisition, Pro Forma Information [Abstract]
Net revenues			4,099,000	5,274,000	12,738,000	14,897,000
Net loss			(1,702,000)	(1,300,000)	(5,139,000)	(2,057,000)
Non-recurring expenses directly attributable to the merger			531,000	275,000	1,933,000	275,000
Settlement of receivables and payables between merging companies							17,000
Gross contractual amounts receivable							232,000
Number of officers whom repayment of notes payable							2
Repayment of each officer notes payable					75,000
Repayment of related party notes payable					$ 150,000
Shares issued to satisfy the remainder of debt (in shares)							82,000